Researchers from the Ottawa Hospital Research Institute (Canada) evaluated the prognostic value of serum NfL levels obtained shortly after MS diagnosis to identify patients likely to have a more aggressive disease course. A total of 67 MS patients were identified whose serum had been collected within 5 years of first MS symptom onset. Median follow-up was 17.4 years. Levels of serum NfL were quantified in all 67 MS patients and in 37 matched controls using a digital immunoassay (SiMoA HD-1 Analyzer, Quanterix).
The median baseline NfL level in MS patients was 10.1 pg/mL, which is 38.5% higher than in controls (7.26 pg/mL, P=0.004). Patients reaching Expanded Disability Status Scale (EDSS) â„4 during follow-up had significantly (73.6%) higher baseline NfL levels than patients with EDSS <4 (P=0.0001). The best cut-off for predicting progression was 7.62 pg/mL. Patients with baseline NfL levels >7.62 pg/mL had a 8.9 times higher risk of developing progressive MS during follow-up (P=0.034; 95% CI 1.2-68.1). Patients in the highest tertile of NfL levels progressed most rapidly (annual EDSS rate 0.16; P=0.004). Patients with baseline NfL levels <7.62 pg/mL had a 4.3 times lower relative risk of significant disability (EDSS score â„4; P=0.001) and a 7.1 times lower risk of reaching the progressive phase of MS (P=0.054).
- Thebault S, et al. Abstract S10.008, AAN 2020.
Posted on
Previous Article
« Epstein-Barr virus-targeted T-cell immunotherapy for progressive MS Next Article
MRI-based clustering of MS patients »
« Epstein-Barr virus-targeted T-cell immunotherapy for progressive MS Next Article
MRI-based clustering of MS patients »
Table of Contents: EAN 2020
Featured articles
Alzheimer's Disease and Other Dementias
Non-Alzheimerâs disease pathophysiology in the elderly
Novel genetic association with resistance to ERC tau deposition
Diastolic dysfunction novel risk factor for cognitive impairment
Epilepsy
Avoidable epilepsy-related mortality remains high
How genetic testing can contribute to epilepsy management
Cenobamate effective in focal epilepsy
Sustained seizure reductions with cannabidiol for Lennox-Gastaut syndrome
Prevalence of autoantibodies in epilepsy almost 10%
Parkinson's Disease
White matter matters in Parkinsonâs disease
Sleep disorders mark PD progression
Directional DBS superior to omnidirectional DBS
Stroke
Benefits of statins to prevent stroke outweigh risks
Extubation after thrombectomy: the sooner, the better
Thrombus location and length predictors of early neurological deterioration
Endovascular treatment in large vessel occlusion stroke patients treated with OAC
Early edoxaban may be safe after cardioembolic stroke
Headache and Pain
Small fibre pathology as biomarker for fibromyalgia
Migraine as a cyclical functional disorder
Reassuring real-world safety profile of 3 CGRP inhibitors
Long-term cardiovascular safety of erenumab
Real-world data for erenumab in Germany
Eptinezumab in chronic migraine and medication-overuse headache
Fremanezumab tolerability in cardiovascular patients with migraine
Effects of galcanezumab on health-related quality of life
Multiple Sclerosis
Imaging to evaluate remyelination and neuroprotection
Serum NfL predicts long-term clinical outcomes in MS
Epstein-Barr virus-targeted T-cell immunotherapy for progressive MS
High NEDA rates after 2 years of ocrelizumab
Switching from natalizumab to moderate- versus high-efficacy DMT
Results of compounds in late stages of development
Alemtuzumab efficacy and safety data of over 9 years
Fampridine treatment results in routine clinical practice
Air pollution is a possible risk factor for MS
Neuromyelitis Optica Spectrum Disorder
Genetic association studies in NMOSD needed
Eculizumab in NMOSD: the PREVENT study
Long-term safety of satralizumab consistent with double-blind periods
Neuromuscular Disorders
Biomarkers predicting motor function in SMA
Sustained benefits of avalglucosidase alfa in late-onset Pompe disease
Efficacy and safety of rituximab in refractory MG corroborated
Related Articles

September 10, 2020
Imaging to evaluate remyelination and neuroprotection
September 9, 2020
Prevalence of autoantibodies in epilepsy almost 10%
September 10, 2020
Switching from natalizumab to moderate- versus high-efficacy DMT
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com